Redmile Group’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Redmile Group’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-254,590	Closed	-$1.26M	–	86
2019 Q2	$1.26M	Hold	254,590	–	–	0.04%	68
2019 Q1	$1.58M	Sell	254,590 -1,883	-0.7%	-$9.1K	0.05%	66
2018 Q4	$864K	Sell	256,473 -168,942	-40%	-$789K	0.03%	64
2018 Q3	$2.77M	Sell	425,415 -789,178	-65%	-$5.87M	0.09%	66
2018 Q2	$9.3M	Buy	1,214,593 +32,200	+3%	+$464K	0.32%	52
2018 Q1	$26.4M	Buy	1,182,393 +202,000	+21%	+$4.48M	1.02%	31
2017 Q4	$12.5M	Buy	980,393 +24,795	+3%	+$364K	0.54%	50
2017 Q3	$14.9M	Sell	955,598 -182,772	-16%	-$2.58M	0.73%	39
2017 Q2	$16M	Buy	1,138,370 +24,210	+2%	+$518K	0.97%	38
2017 Q1	$22.5M	Buy	+1,114,160	New	+$23.6M	1.46%	26

Other funds holding JNCE

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group's JNCE Position: Q3 2019 in Review

Redmile Group sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2019, closing a stake of 254,590 shares — an estimated $1.26M sold.

Redmile Group first reported a position in JNCE in Q1 2017 and held it in 10 quarters. The position peaked at $26.4M in Q1 2018. 77 funds tracked by Wall St. Rank hold JNCE as of Q3 2019.

Redmile Group reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
Redmile Group sold 254,590 Jounce Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $1.26M.
Redmile Group first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 10 quarters.
Redmile Group's Jounce Therapeutics, Inc. Common Stock position peaked at $26.4M in Q1 2018.
77 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Redmile Group's 13F filing for Q3 2019, filed 14 Nov 2019.